Five years in a row. That is how long Dr. Meenakshi Kanwar Chauhan, a researcher from Una district in Himachal Pradesh, has held her place among the world's top 2% of scientists — a ranking jointly produced by Stanford University and academic publisher Elsevier. BJP MP Anurag Thakur, whose Hamirpur Lok Sabha constituency covers Una district, celebrated the achievement on Sunday, 18 October 2026, calling it an honour 'not only for devbhoomi Himachal Pradesh, but for the whole nation.'

From Una to a global citation benchmark

The Stanford-Elsevier list uses standardised citation metrics drawn from the Scopus database to identify the most impactful researchers across every scientific discipline worldwide. Making the list once is a mark of sustained scholarly output. Doing so for five consecutive years signals a body of work that the international research community keeps returning to. Dr. Chauhan's repeated inclusion places her in genuinely rare company.

Her institutional base is DIPSAR — the Delhi Institute of Pharmaceutical Sciences and Research, a central government institution that has long been one of India's foremost hubs for pharmacy education and applied research. The work that earned her this recognition cuts across some of the most technically demanding frontiers in modern drug development: pharmaceutical nanotechnology, novel drug delivery systems, ocular drug delivery, transdermal drug delivery, and targeted medicine delivery. Each of these fields is directly relevant to the challenge of getting the right drug to the right tissue at the right concentration — a problem that shapes everything from glaucoma treatment to cancer therapy.

Why ocular and transdermal delivery matter

Delivering drugs through the eye or the skin sounds deceptively simple. It is not. The cornea is one of the body's most effective barriers; most conventional eye drops lose the majority of their active compound before it reaches the target tissue. The skin is designed, at the molecular level, to keep substances out. Nanoparticle-based formulations — the territory Dr. Chauhan's research occupies — are among the most promising tools for overcoming these barriers without invasive procedures. Research in this space has direct implications for patients managing chronic eye disease, pain conditions, and hormone disorders.

Himachal's quiet scientific footprint

Thakur's post frames the recognition through the lens of regional identity, invoking the phrase 'devbhoomi Himachal Pradesh' — literally 'the land of the gods' — a cultural shorthand that carries deep pride for residents of the hill state. The framing is deliberate: scientists of Himachali origin who build careers at national institutions tend to be acknowledged primarily by those institutions, not their home districts. By naming Una district explicitly, Thakur anchors an abstract global ranking in a concrete local geography, making the achievement legible to constituents who might never encounter the Stanford-Elsevier list on their own.

It also fits a broader pattern. Indian researchers embedded in central institutions like DIPSAR have quietly contributed to applied pharmaceutical science for decades, often with limited public visibility outside specialist circles. A recognition like this — amplified through political channels — can shift that.

The woman behind the ranking

Dr. Chauhan represents precisely the profile that India's pharmaceutical research ecosystem needs more of: a scientist doing applied, translational work — the kind that moves ideas from a laboratory bench toward a patient's bedside — while maintaining the citation record that signals global relevance. Five consecutive appearances on the Stanford-Elsevier list are not the result of a single breakthrough paper. They reflect a research programme that consistently produces work others build on.

As drug delivery science races toward increasingly personalised and targeted therapies, researchers who have spent years mapping the physics and chemistry of barriers like the cornea and the skin will be central to what comes next. Dr. Chauhan is one of them — and now, a wider audience knows it.